Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Low Skeletal Muscle Mass and Clinical Outcomes in Chronic Obstructive Pulmonary Disease

  • Yong Jun Choi (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Hye Jung Park (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Jae Hwa Cho (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Min Kwang Byun (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine)
  • Received : 2023.01.13
  • Accepted : 2023.08.05
  • Published : 2023.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: In patients with chronic obstructive pulmonary disease (COPD), decreased muscle mass is a frequently encountered comorbidity in clinical practice. However, the evaluation of muscle mass in patients with COPD in real-world practice is rare. Methods: We retrospectively reviewed the electronic medical records of all patients with COPD who underwent bioelectrical impedance analysis at least once between January 2011 and December 2021 in three hospitals. Then, we analyzed the performance rate of muscle mass measurement in the patients and the correlation between muscle mass, clinical parameters, and COPD prognosis. Results: Among the 24,502 patients with COPD, only 270 (1.1%) underwent muscle mass measurements. The total skeletal muscle mass index was significantly correlated with albumin, alanine transaminase, and creatinine to cystatin C ratio in patients with COPD (r=0.1614, p=0.011; r=0.2112, p=0.001; and r=0.3671, p=0.001, respectively). Acute exacerbation of COPD (AE COPD) was significantly correlated with muscle mass, especially the truncal skeletal muscle mass index (TSMI) in males (r=-0.196, p=0.007). In the multivariate analysis, TSMI and cystatin C were significant risk factors for AE COPD (hazard ratio, 0.200 [95% confidence interval, CI, 0.048 to 0.838] and 4.990 [95% CI, 1.070 to 23.278], respectively). Conclusion: Low muscle mass negatively affects the clinical outcomes in patients with COPD. Despite its clinical significance, muscle mass measurement is performed in a small proportion of patients with COPD. Therefore, protocols and guidelines for the screening of sarcopenia in patients with COPD should be established.

Keywords

References

  1. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020;21:300-7.  https://doi.org/10.1016/j.jamda.2019.12.012
  2. Benz E, Trajanoska K, Lahousse L, Schoufour JD, Terzikhan N, De Roos E, et al. Sarcopenia in COPD: a systematic review and meta-analysis. Eur Respir Rev 2019; 28:190049. 
  3. Perrot L, Greil A, Boirie Y, Farigon N, Mulliez A, Costes F, et al. Prevalence of sarcopenia and malnutrition during acute exacerbation of COPD and after 6 months recovery. Eur J Clin Nutr 2020;74:1556-64.  https://doi.org/10.1038/s41430-020-0623-6
  4. Costa TM, Costa FM, Moreira CA, Rabelo LM, Boguszewski CL, Borba VZ. Sarcopenia in COPD: relationship with COPD severity and prognosis. J Bras Pneumol 2015;41:415-21.  https://doi.org/10.1590/S1806-37132015000000040
  5. Maltais F, Decramer M, Casaburi R, Barreiro E, Burelle Y, Debigare R, et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014;189:e15-62.  https://doi.org/10.1164/rccm.201402-0373ST
  6. Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003;58:752-6.  https://doi.org/10.1136/thorax.58.9.752
  7. Gosker HR, Langen RC, Simons SO. Role of acute exacerbations in skeletal muscle impairment in COPD. Expert Rev Respir Med 2021;15:103-15.  https://doi.org/10.1080/17476348.2021.1843429
  8. Byun MK, Cho EN, Chang J, Ahn CM, Kim HJ. Sarcopenia correlates with systemic inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2017;12:669-75.  https://doi.org/10.2147/COPD.S130790
  9. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9.  https://doi.org/10.1097/01.mlr.0000182534.19832.83
  10. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16-31.  https://doi.org/10.1093/ageing/afy169
  11. Wallengren O, Bosaeus I, Frandin K, Lissner L, Falk Erhag H, Wetterberg H, et al. Comparison of the 2010 and 2019 diagnostic criteria for sarcopenia by the European Working Group on Sarcopenia in Older People (EWGSOP) in two cohorts of Swedish older adults. BMC Geriatr 2021;21:600. 
  12. Limpawattana P, Inthasuwan P, Putraveephong S, Boonsawat W, Theerakulpisut D, Sawanyawisuth K. Sarcopenia in chronic obstructive pulmonary disease: a study of prevalence and associated factors in the Southeast Asian population. Chron Respir Dis 2018;15:250-7.  https://doi.org/10.1177/1479972317743759
  13. Baumgartner RN, Koehler KM, Romero L, Garry PJ. Serum albumin is associated with skeletal muscle in elderly men and women. Am J Clin Nutr 1996;64:552-8.  https://doi.org/10.1093/ajcn/64.4.552
  14. Zinellu E, Fois AG, Sotgiu E, Mellino S, Mangoni AA, Carru C, et al. Serum albumin concentrations in stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Clin Med 2021;10:269. 
  15. Qin J, Qin Y, Wu Y, Wei A, Luo M, Liao L, et al. Application of albumin/globulin ratio in elderly patients with acute exacerbation of chronic obstructive pulmonary disease. J Thorac Dis 2018;10:4923-30.  https://doi.org/10.21037/jtd.2018.07.47
  16. Shi T, Feng L. Blood biomarkers associated with acute type II respiratory failure in COPD: a meta-analysis. Clin Respir J 2022;16:75-83.  https://doi.org/10.1111/crj.13464
  17. Vespasiani-Gentilucci U, De Vincentis A, Ferrucci L, Bandinelli S, Antonelli Incalzi R, Picardi A. Low alanine aminotransferase levels in the elderly population: frailty, disability, sarcopenia, and reduced survival. J Gerontol A Biol Sci Med Sci 2018;73:925-30.  https://doi.org/10.1093/gerona/glx126
  18. Gallo P, De Vincentis A, Bandinelli S, Ferrucci L, Picardi A, Antonelli Incalzi R, et al. Combined evaluation of aminotransferases improves risk stratification for overall and cause-specific mortality in older patients. Aging Clin Exp Res 2021;33:3321-31.  https://doi.org/10.1007/s40520-021-01979-9
  19. He Y, Ding F, Yin M, Zhang H, Hou L, Cui T, et al. High serum AST/ALT ratio and low serum INS*PA product are risk factors and can diagnose sarcopenia in middle-aged and older adults. Front Endocrinol (Lausanne) 2022;13:843610. 
  20. Choi YJ, Kwon DS, Kim T, Cho JH, Kim HJ, Byun MK, et al. Low alanine aminotransferase as a risk factor for chronic obstructive pulmonary disease in males. Sci Rep 2021;11:14829. 
  21. Lasman N, Shalom M, Turpashvili N, Goldhaber G, Lifshitz Y, Leibowitz E, et al. Baseline low ALT activity is associated with increased long-term mortality after COPD exacerbations. BMC Pulm Med 2020;20:133. 
  22. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40:221-6.  https://doi.org/10.1053/ajkd.2002.34487
  23. Inker LA, Titan S. Measurement and estimation of GFR for use in clinical practice: core curriculum 2021. Am J Kidney Dis 2021;78:736-49.  https://doi.org/10.1053/j.ajkd.2021.04.016
  24. Lin YL, Chen SY, Lai YH, Wang CH, Kuo CH, Liou HH, et al. Serum creatinine to cystatin C ratio predicts skeletal muscle mass and strength in patients with non-dialysis chronic kidney disease. Clin Nutr 2020;39:2435-41.  https://doi.org/10.1016/j.clnu.2019.10.027
  25. Zheng C, Wang E, Li JS, Xie K, Luo C, Ge QY, et al. Serum creatinine/cystatin C ratio as a screening tool for sarcopenia and prognostic indicator for patients with esophageal cancer. BMC Geriatr 2022;22:207. 
  26. Hashimoto Y, Takahashi F, Okamura T, Osaka T, Okada H, Senmaru T, et al. Relationship between serum creatinine to cystatin C ratio and subclinical atherosclerosis in patients with type 2 diabetes. BMJ Open Diabetes Res Care 2022;10:e002910. 
  27. Hirai K, Tanaka A, Homma T, Goto Y, Akimoto K, Uno T, et al. Serum creatinine/cystatin C ratio as a surrogate marker for sarcopenia in patients with chronic obstructive pulmonary disease. Clin Nutr 2021;40:1274-80.  https://doi.org/10.1016/j.clnu.2020.08.010
  28. Chai L, Feng W, Zhai C, Shi W, Wang J, Yan X, et al. The association between cystatin C and COPD: a meta-analysis and systematic review. BMC Pulm Med 2020;20:182.